Aims/hypothesis Type 2 diabetes is characterised by decreased HDL levels, as well as the level of apolipoprotein A-I (apoA-I), the main apolipoprotein of HDLs. Pharmacological elevation of HDL and apoA-I levels is associated with improved glycaemic control in patients with type 2 diabetes. This is partly due to improved glucose uptake in skeletal muscle. Methods This study used kinetic modelling to investigate the impact of increasing plasma apoA-I levels on the metabolism of glucose in the db/db mouse model.
Introduction
Type 2 diabetes is characterised by decreased HDLcholesterol levels, as well as a decreased level of apolipoprotein A-I (apoA-I), the main HDL apolipoprotein [1] .
Therapeutic interventions that increase plasma HDL levels improve glycaemic control in patients with type 2 diabetes [2, 3] , and treatment with HDL or apoA-I has been shown to increase glucose uptake into skeletal muscle [4, 5] and adipose tissue [6] . Furthermore, treatment with HDL or apoA-I increases insulin secretion and production in isolated pancreatic islets and insulinoma beta cell lines [7, 8] . Recent studies have demonstrated that both single and repeated doses of apoA-I can also improve insulin resistance in fat-fed C57Bl6 mice [9, 10] , as can overexpression of apoA-I [11] .
Here, we have established a methodology using [
18 F]FDG and positron emission tomography/computed tomography (PET/CT) imaging, together with kinetic modelling, to quantify the in vivo, real-time impact of apoA-I treatment on glucose uptake into skeletal muscle. The db/db mouse is a wellestablished animal model of type 2 diabetes [12] . While previous studies have been conducted using [ 18 F]FDG to examine glucose uptake in db/db mice as an insulin resistant animal model, these studies only quantified endpoint uptake in the heart [13] and cardiac and skeletal muscle [14] and did not extend to determination of kinetics. Kinetic modelling of PET dynamic studies permits analysis beyond simple characterisation of global glucose uptake and determines the glucose influx and phosphorylation rates in specific tissues.
Methods
Mice B6/BKS(D)-Lepr db /J (db/db) mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). The experiments were conducted on 6-week-old male homozygous mice maintained on standard chow in pathogen-free conditions. All procedures were approved by the Sydney Local Health District and University of Sydney Animal Ethics Committees and followed the NIH Guide for the care and use of laboratory animals, Eighth edition (2011). Mice were randomly assigned to treatment groups by coin flip.
ApoA-I treatment Mice received a single i.p. injection of human apoA-I (40 mg/kg, CSL Pty, Parkville, Australia) or an equivalent volume of PBS (n = 5/group). Blood was sampled from the lateral tail vein over 24 h and plasma apoA-I concentrations were determined by an ELISA that was specific for human apoA-I (Cell Biolabs, San Diego, CA, USA).
Glucose tolerance test Mice were fasted for 3 h prior to receiving human apoA-I (40 mg/kg i.p.) or an equivalent volume PBS (n = 7/group). After a further 2 h, glucose (1 g D-glucose/kg; Sigma-Aldrich, St Louis, MO, USA) was injected i.p. Blood glucose levels were determined using an Accu-Chek Performa glucometer (Roche, Basel, Switzerland).
Insulin tolerance test Random fed mice received a single i.p. injection of human apoA-I (40 mg/kg) or PBS (n = 6/group). After a further 2 h insulin (3 U human insulin/kg; SigmaAldrich) was injected i.p. and blood glucose levels measured as above.
Ex vivo skeletal muscle glucose uptake Fasted mice were treated with apoA-I (40 mg/kg i.p.) or PBS (n = 6/group) and euthanised 2 h later. The gastrocnemius muscle was removed and 2-deoxy[ 3 H]glucose (PerkinElmer, Waltham, MA, USA) uptake was quantified [15] . The muscle was incubated for 1 h at 37°C with or without insulin (0.3 μmol/l), transferred to fresh buffer containing 1 mmol/l 2-deoxy[ 3 H]glucose (37 kBq/ml) and 7 mmol/l D-[ 14 C]-mannitol (14.8 kBq/ml; PerkinElmer) with or without insulin (0.3 μmol/l) for 10 min. Glucose uptake was terminated by immersion in ice-cold buffer containing 80 μmol/l cytochalasin B (SigmaAldrich). White and red muscle was isolated, snap frozen in liquid nitrogen and stored at −80°C for further use. Muscle samples were homogenised, and the 3 H and 14 C content determined by liquid scintillation counting.
Small-animal PET study Fasted mice received an i.p. injection of apoA-I (40 mg/kg) or PBS (n = 4/group). After 2 h, the mice were anaesthetised with isoflurane administered via precision vaporiser (induction, 5%; maintenance, 1.5-2%), and maintained in a surgical plane of anaesthesia for the duration of the procedure. For mice treated with insulin, a dose of 3 U human insulin/kg was administered s.c. 30 min before the start of the PET/CT scan. After positioning the mice in the gantry of an Inveon PET/CT Scanner (Siemens, Munich, Germany), a 60 min PET scan commenced immediately after injection of [ 18 F]FDG (10-18 MBq, pH 6.6-7.0, 0.1 ml; PETNET Solutions, Lucas Heights, Australia) via the lateral tail vein. After completing the PET scan, a CT scan was performed to allow the co-registration of radiotracer uptake with tissues.
Image reconstruction Image reconstruction was performed using IAW 2.02 (Siemens). The listmode data was histogrammed into 16 frames (6 × 10 s, 4 × 60 s, 1 × 300 s, 5 × 600 s) for the period 0-60 min after tracer injection. Emission sinograms were reconstructed using 2D-filter back projection with a zoom of 1.5. The reconstructed images consisted of 16 frames of a 128 × 128 × 159 matrix with a voxel size of 0.52 × 0.52 × 0.796 mm 3 . They were corrected for attenuation (CT-based), scatter, randoms, normalisation, isotope decay, branching ratio, deadtime and were calibrated to Bq/ml. Input function The input function was derived from the image by placing an ROI over the inferior vena cava. Due to the size of the vena cava in a mouse, it is necessary to correct for the system point spread function (PSF). This was achieved by using the reblurred Van Cittert deconvolution method [16] and deconvolving the estimated system PSF for five iterations. Post deconvolution images were used to create an input function time-activity curve from dynamic frames. The FDG twotissue compartment model requires the plasma input function. The blood input function was converted to the plasma input function using the following equation [17] :
Modelling The FDG two-tissue compartment method with k 4 = 0 was used for modelling. The blood, plasma and gastrocnemius total activity counts were loaded into PMOD, version 3.17 (PMOD Technologies, Zürich, Switzerland) and the FDG model fitted. During fitting of the parameters, the V b (blood volume fraction) was initially fixed at 2%, and dispersion effect [18] was applied to the input functions as proposed by Oikonen [19] . The optimum value for dispersion was found by minimising the χ 2 value for the FDG model. A final fit was made using a floating V b and the optimised dispersion value, this yielded the rate constants (k 1 -k 3 ) and influx constant was calculated as
. The researcher conducting the kinetic modelling was blinded to treatment groups.
Cell culture L6 rat skeletal muscle cells were cultured at 37°C in a humidified, 5% CO 2 atmosphere with α-MEM medium supplemented with 10% (vol./vol.) FCS. Cells were differentiated as previously described [6] .
Hexokinase activity assay Cells were serum starved for 6 h prior to treatment with apoA-I (final concentration 1 mg/ml) or equivalent volume PBS. After 1.5 h, cells were treated with insulin (final concentration 0.1 μmol/l) or equivalent volume PBS for a further 30 min. Hexokinase activity was determined by measuring NADH production in lysates after 30 min incubation period with a hexokinase assay kit (Abcam, Cambridge, MA, USA).
GLUT4 translocation GLUT4 translocation was measured as described previously [20] . L6 cells were incubated at 37°C for 2 h with or without apoA-I (1 mg/ml). Primary anti-GLUT4, specific for the extracellular domain (1:100, Santa Cruz Biotechnology, Dallas, TX, USA), and secondary DyLight488 donkey anti-goat (1:500, Abcam) antibodies were incubated together for 10 min at room temperature. Cells were washed with PBS and incubated with the antibody complex in the presence and absence of insulin (0.1 μmol/l) for 30 min. Cells were analysed using a FACSverse flow cytometer (BD Biosciences, San Jose, CA, USA).
Statistical analysis All data presented are mean ± SD. Data was analysed using Prism 6 (GraphPad, La Jolla, CA, USA). A p value <0.05 was considered statistically significant. Glucose and insulin tolerance tests were compared using unpaired, two-tailed t tests. Mann-Whitney tests were used to compare the kinetic parameters between groups. Hexokinase activity and GLUT4 translocation experiments were compared by ANOVA and a Tukey's multiple comparison test.
Results
ApoA-I increases glucose tolerance and improves insulin sensitivity in db/db mice At 2 h after receiving a single bolus of apoA-I (40 mg/kg i.p.) the plasma level of human apoA-I in db/db mice was maximal (65.24 ± 14.42 μg/ml), and remained relatively constant for a further 5 h (Fig. 1a) . At 24 h after the injection, the apoA-I concentration had decreased to 34.85 ± 9.68 μg/ml. As plasma levels of apoA-I were maximal at 2 h, this time point was used in all subsequent experiments.
Treatment with apoA-I improved glucose tolerance in the db/db mice (white circles) compared with saline (154 mmol/l NaCl)-treated animals (black squares) (AUC 2574 ± 70 mmol/ l × min vs 2927 ± 137 mmol/l × min for apoA-I and PBS treatment, respectively; p < 0.05) (Fig. 1b) . When subjected to an insulin tolerance test, blood glucose levels (black squares) decreased by 25%, from 10.83 ± 1.98 mmol/l to 8.13 ± 1.97 mmol/l in the PBS-treated mice and by 43%, from 9.62 ± 0.64 mmol/l to 5.52 ± 1.09 mmol/l, in the apoA-Itreated mice (white circles) (AUC 388.8 ± 23.8 mmol/l × min vs 194.1 ± 19.6 mmol/l × min for apoA-I and PBS treatment, respectively; p < 0.001) (Fig. 1c) .
ApoA-I increases ex vivo glucose uptake by skeletal muscle in db/db mice The ability of apoA-I to increase glucose uptake by skeletal muscle in insulin resistant db/db mice was also investigated. Ex vivo glucose uptake by red and white gastrocnemius muscle from PBS-treated db/db mice was not significantly increased by incubation with insulin (Fig. 2 , black bars). When a single i.p. injection of apoA-I was administered to the animals 2 h prior to euthanasia, insulinindependent glucose uptake in red gastrocnemius muscle increased from 2.91 ± 1.09 nmol mg −1 h −1 for the PBS-treated animals to 5.10 ± 0.42 nmol mg −1 h −1 (Fig. 2 , white bars, p < 0.001), while insulin-independent glucose uptake into white muscle increased from 3.58 ± 1.17 nmol mg
In the presence of insulin, glucose uptake into red muscle from the control animals was 3.02 ± 0.74 nmol mg F]FDG into the gastrocnemius muscle was significantly increased in mice that had been pretreated with apoA-I compared with control (maximal activity at 270 s post injection; 0.93 ± 0.08 vs 1.56 ± 0.19% injected dose for PBS and apoA-I treated animals, respectively; p < 0.05) (Fig. 3a, b) . While treatment of mice with insulin 30 min before infusion of [ 18 F]FDG altered the pattern of tracer uptake, the uptake remained higher in animals treated with apoA-I compared with PBS-treated controls (maximal activity at 450 s post injection; 1.02 ± 0.04 vs 1.35 ± 0.05% injected dose for PBS and apoA-I-treated animals, respectively; p < 0.05) (Fig. 3c, d ). While treatment with apoA-I alone had no significant impact on plasma levels of [ (Fig. 3e) , treatment of mice with apoA-I and insulin significantly increased the rate of exit of [ 18 F]FDG from the plasma compared with mice that received only insulin (maximal activity at 55 s post injection 64.89 ± 4.45 vs 45.00 ± 4.21% of the injected dose for PBS and apoA-I-treated animals, respectively, p < 0.05) (Fig. 3f) . This increased rate of [ Kinetic modelling To further understand the impact of apoA-I treatment on the altered [ 18 F]FDG uptake patterns observed in skeletal muscle and the effects on the level of the tracer in plasma, data were fitted to a two-tissue compartment, threerate constant model (Fig. 4a) , with compartments corresponding to arterial plasma [ (Fig. 4b) , although there was a trend towards higher values in animals Fig. 2 ApoA-I increases glucose disposal in skeletal muscle in db/db mice. Male db/db mice were fasted for 3 h prior to receiving an i.p. injection of lipid-free apoA-I (40 mg/kg; white bars) or PBS (black bars). The mice were fasted for a further 2 h then euthanised. The gastrocnemius muscle was removed, red and white components were isolated, and glucose uptake was determined as described in the Methods section. **p < 0.01, ***p < 0.001 for muscles from animals treated with apoA-I compared with muscles from animals treated with PBS treated with apoA-I relative to control. Additionally, no significant change in the rate of transport from the intracellular space to plasma (k 2 ) was observed between treatment groups (Fig. 4c) , p < 0.05). The influx constant (K i ) was not significantly different between PBS and apoA-I-treated mice (Fig. 4e) . Similar to k 3 , pretreatment with apoA-I significantly increased the K i in the insulin-treated animals compared with the PBStreated animals (3.70 ± 0.65 × 10 −3 vs 2.01 ± 0.28 × 10 −3 ml
, respectively; p < 0.05).
ApoA-I treatment increases hexokinase activity in vitro
In an effort to understand the mechanism responsible for the increased rate of [ 18 F]FDG phosphorylation in apoA-Itreated db/db mice, we examined the impact of apoA-I treatment on L6 rat skeletal muscle cells. Treatment of cells with apoA-I alone did not significantly increase hexokinase activity (Fig. 5a ). Treatment with insulin significantly increased hexokinase activity (100.00 ± 8.32% vs 192.01 ± 8.32% for PBS alone and PBS insulin-treated groups; p < 0.001) and was further increased in apoA-I-pretreated cells (260.14 ± 6.98%; p < 0.005 relative to PBS insulin alone). Treatment of L6 cells with insulin significantly increased cell surface GLUT4 levels (100.00 ± 12.22% vs 241.54 ± 18.96) (Fig. 5b) . However, treatment with apoA-I for 2 h had no impact on GLUT4 translocation, either in the presence or absence of insulin.
Discussion
In this study we have demonstrated that a single infusion of apoA-I significantly increases the rate of glucose uptake by skeletal muscle in db/db mice. Further, we have used real-time PET imaging to characterise the impact of apoA-I and insulin treatment on glucose uptake from the plasma into the gastrocnemius muscle in db/db mice. This proof of principle study has considerable flexibility and can be extended into studies of multiple organs and used longitudinally. No significant increase in glucose uptake was observed when muscle samples were treated with insulin alone, which is a reflection of the insulin resistant state of db/db mice. Treatment of the mice with apoA-I alone significantly increased glucose uptake. When the mice were treated with apoA-I and the skeletal muscle was subsequently treated with insulin, glucose uptake was increased over and above that of apoA-I alone. This is indicative of apoA-I not only increasing the glucose uptake, but also improving insulin sensitivity. This is consistent with previous reports of apoA-I increasing skeletal muscle glucose uptake in both the presence and absence of insulin [2, 4] .
HDL and apoA-I can activate a number of cell signalling pathways that have been linked to increased glucose uptake and insulin sensitivity. These include the AMP kinase pathway [21] [22] [23] [24] [25] [26] [27] , which is known to be activated by apoA-I [4] . HDL can also activate phosphatidylinositol-3 kinase (PI3K)/ Akt via scavenger receptor class B type I (SR-BI) [28] , which increases the trafficking of GLUT4 from intracellular stores to the cell surface [6] , thereby increasing cellular glucose uptake. We have also previously demonstrated that apoA-I can activate protein kinase A (PKA) [8] , and PKA-mediated phosphorylation of peroxisome proliferator-activated receptor α has been shown to improve insulin sensitivity in rats [29] . The findings from the ex vivo skeletal muscle glucose uptake experiment suggested that apoA-I increased glucose uptake into skeletal muscle in an insulin-dependent and insulinindependent manner. To gain further insight into the impact of apoA-I treatment on glucose uptake and metabolism in skeletal muscle, we used kinetic analysis to model the uptake of [ 18 F]FDG from the plasma into the muscle. Rather than collecting numerous arterial blood samples during the PET study, which is impractical due to the small blood volume of mice, we derived the model input function from the reconstructed image data using an ROI over the vena cava [30] . To ensure the robustness of our variable estimates, PET images were deconvolved to limit partial volume effects [16] and the dispersion of the input function was included as a fit variable during kinetic modelling. Mouse input functions have previously been determined using the whole heart [31] as well as heart, liver and a blood samples [32] .
A limitation of our [
18 F]FDG PET study is that it cannot determine whether small changes in k 1 are due to changes in blood flow in gastrocnemius tissue or altered glucose transport across the cell membrane. Multi-tracer approaches using [ 15 The time-activity curves for the gastrocnemius muscle of db/db mice treated with apoA-I showed increased uptake relative to control treatment in both the absence and presence of insulin. Furthermore, apoA-I and insulin treatment led to an increased rate of exit of [ 18 F]FDG from the plasma compartment into tissue, relative to mice treated with insulin alone. As the rate of [ 18 F]FDG uptake into the gastrocnemius (k 1 ) cannot account for this alone, it is likely to be due to increased cumulative whole body uptake, potentially via an HDL-mediated increase in production of the vasodilator endothelial nitric oxide synthase [36] .
The rate of transport of [ While previous studies have suggested HDL can improve glucose transport via increasing cell surface GLUT4 levels [5, 6] , these studies were conducted in vitro and did not observe increased glucose transport with apoA-I treatment. HDL has previously been reported to increase GLUT4 translocation to the cell surface via SR-BI and Akt [6] . However, apoA-I does not activate the Akt pathway [8] and this may explain the lack of a significant increase in k 1 in vivo and in L6 rat skeletal muscle cells treated with apoA-I.
While apoA-I treatment alone had no impact on the rate of [ 18 F]FDG phosphorylation (k 3 ), treatment with apoA-I significantly increased the rate of insulin-dependent glucose phosphorylation. This appears to be somewhat contradictory to previous findings that glucose transport is rate limiting for glucose disposal in skeletal muscle [34] . Hexokinase II (HK-II), the primary enzyme responsible for glucose phosphorylation in skeletal muscle, is phosphorylated by insulindependent activation of the Akt/PI3K signalling pathway, resulting in increased HK-II-mitochondrial association [37] , which in turn increases HK-II activity [38] [39] [40] . Using the L6 rat skeletal muscle cell line, we confirmed that treatment of cells with apoA-I increased insulin-mediated HK-II activity, providing further evidence that while not able to activate the Akt/PI3K pathway directly, apoA-I potentiates insulinmediated activation of HK-II activity. As such, this study suggests that the primary mechanism responsible for increased apoA-I-mediated insulin sensitivity is increased phosphorylation of glucose via increased potentiation of the insulin signalling pathway.
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